A new vaccine “tailored” to target probable future mutations of the Covid-19 coronavirus will likely be needed by the middle of 2022, according to the head of BioNTech, the biotechnology company that developed the Pfizer shot. The German firm’s CEO, Uğur Şahin, told the Financial Times that Covid-19 variants such as the Delta strain were […]
